CLYM

Company Overview — What Does Climb Bio, Inc. Do?

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware. Climb Bio, Inc. (CLYM) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Aoife M. Brennan and employs approximately 9 people. With a market capitalization of $332M, CLYM is one of the notable companies in the Healthcare sector.

Climb Bio, Inc. (CLYM) Stock Rating — Reduce (April 2026)

As of April 2026, Climb Bio, Inc. receives a Reduce rating with a composite score of 36.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CLYM ranks #2,046 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Climb Bio, Inc. ranks #226 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLYM Stock Price and 52-Week Range

Climb Bio, Inc. (CLYM) currently trades at $8.25. The stock gained $0.20 (2.5%) in the most recent trading session. The 52-week high for CLYM is $8.04, which means the stock is currently trading 2.6% from its annual peak. The 52-week low is $1.05, putting the stock 685.7% above its annual trough. Recent trading volume was 828K shares, suggesting relatively thin trading activity.

Is CLYM Overvalued or Undervalued? — Valuation Analysis

Climb Bio, Inc. (CLYM) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.04x, versus the sector average of 2.75x.

At current multiples, Climb Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Climb Bio, Inc. Profitability — ROE, Margins, and Quality Score

Climb Bio, Inc. (CLYM) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -30.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLYM Debt, Balance Sheet, and Financial Health

Climb Bio, Inc. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 15.16x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $26M.

CLYM has a beta of 1.28, meaning it is more volatile than the broader market — a $10,000 investment in CLYM would be expected to move 27.6% more than the S&P 500 on any given day. The stability factor score for Climb Bio, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Climb Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Climb Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.88. Net income for the quarter was $-51M. Operating income came in at $-60M.

In FY 2025, Climb Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.88. Net income for the quarter was $-60M. Operating income came in at $-68M.

In Q3 2025, Climb Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-13M. Operating income came in at $-15M.

In Q2 2025, Climb Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-9M. Operating income came in at $-11M.

Over the past 8 quarters, Climb Bio, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CLYM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLYM Dividend Yield and Income Analysis

Climb Bio, Inc. (CLYM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CLYM Momentum and Technical Analysis Profile

Climb Bio, Inc. (CLYM) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 21/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CLYM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Climb Bio, Inc. (CLYM) ranks #226 out of 838 stocks based on the Blank Capital composite score. This places CLYM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CLYM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLYM vs S&P 500 (SPY) comparison to assess how Climb Bio, Inc. stacks up against the broader market across all factor dimensions.

CLYM Next Earnings Date

No upcoming earnings date has been announced for Climb Bio, Inc. (CLYM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLYM? — Investment Thesis Summary

The quantitative profile for Climb Bio, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, Climb Bio, Inc. (CLYM) earns a Reduce rating with a composite score of 36.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLYM stock.

Related Resources for CLYM Investors

Explore more research and tools: CLYM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLYM head-to-head with peers: CLYM vs AZN, CLYM vs SLGL, CLYM vs VMD.